

1 **No evidence for intervention-associated DNA methylation changes in monocytes of**
2 **patients with posttraumatic stress disorder or anorexia nervosa**

3
4 Elisabeth Hummel^{1¶}, Magdeldin Elgizouli^{2¶}, Jasmin Beygo², Johanna Giuranna³, Maurizio
5 Sicorello⁴, Elsa Leitão², Christopher Schröder^{2,5}, Michael Zeschnigk², Svenja Müller¹, Dana
6 Öztürk³, Manuel Föcker⁶, Stephan Herpertz⁷, Johannes Hebebrand³, Dirk Moser¹, Henrik Kessler⁷,
7 Bernhard Horsthemke^{2*}, Anke Hinney^{3*}, Robert Kumsta^{1*}

8
9
10 ¹Department of Genetic Psychology, Faculty of Psychology, Ruhr University Bochum, Germany

11 ²Institute of Human Genetics, University of Duisburg-Essen, University Hospital Essen, Essen, Germany

12 ³Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital
13 Essen, University of Duisburg-Essen, Germany

14 ⁴Department of Psychosomatic Medicine and Psychotherapy, Central Institute of Mental Health, Medical
15 Faculty Mannheim, Heidelberg University, Germany

16 ⁵Genome Informatics, Institute of Human Genetics, University of Duisburg-Essen, University Hospital Essen,
17 Essen, Germany

18 ⁶Department of Child and Adolescent Psychiatry, Psychosomatics and Psychotherapy, University Hospital
19 Münster, Germany

20 ⁷Department of Psychosomatic Medicine and Psychotherapy, LWL-University Hospital, Ruhr University Bo-
21 chum, Germany

22
23 *Correspondence: bernhard.horsthemke@uni-due.de, anke.hinney@uni-due.de, robert.kumsta@rub.de

24
25
26 ¶These authors contributed equally

28 **Abstract**

29 DNA methylation patterns can be responsive to environmental influences. This observation has
30 sparked interest in the potential for psychological interventions to influence epigenetic processes.
31 Recent studies have observed correlations between DNA methylation changes and therapy out-
32 come. However, most did not control for changes in cell composition from pre- to post-therapy.
33 This study had two aims: first, we sought to replicate therapy-associated changes in DNA methyl-
34 ation of commonly assessed candidate genes in isolated monocytes from 60 female patients with
35 post-traumatic stress disorder (PTSD) using targeted deep bisulfite sequencing (DBS). Our se-
36 cond, exploratory goal was to identify novel genomic regions with substantial pre-to-post interven-
37 tion DNA methylation changes by performing whole-genome bisulfite sequencing (WGBS) in two
38 patients with PTSD and three patients with anorexia nervosa (AN) before and after intervention.
39 Equivalence testing and Bayesian analyses provided evidence against physiologically meaningful
40 intervention associated DNA methylation changes in monocytes of PTSD patients in commonly
41 investigated target genes (*NR3C1*, *FKBP5*, *SLC6A4*, *OXTR*). Furthermore, WGBS yielded only a
42 limited set of candidate regions with suggestive evidence of differential methylation pre- to post-
43 therapy. These differential methylation patterns did not prove replicable when investigated in the
44 entire cohort. We conclude that there is no evidence for major, recurrent intervention-associated
45 DNA methylation changes in the investigated genes in monocytes of patients with either PTSD or
46 AN.

47

48 **Author Summary**

49 Many mental health problems have developmental origin, and epigenetic mechanisms have
50 been proposed to explain the link between stressful or adverse experiences and subsequent
51 health outcomes. More recently, studies have begun to examine whether psychological ther-
52 apies might influence or even reverse supposedly acquired DNA methylation marks. Correlat-
53 ions between response to therapy and DNA methylation changes in peripheral tissue have
54 been reported; however, these results might be confounded by differences in cell composi-
55 tion between time points and not reflect true DNA methylation changes. Here, we attempted
56 to replicate previous reported results in a homogenous cell population (monocytes) and fur-
57 ther to identify novel intervention-responsive regions in the whole genome in patients with
58 post-traumatic stress disorder (PTSD) and anorexia nervosa (AN).

59 Our results showed that the improvement in symptomatology in PTSD and AN patients was
60 not reflected in changes in DNA methylation in monocytes, neither in the previously studied
61 candidate genes nor in the regions identified by whole-genome bisulfite sequencing. This
62 study provides evidence against DNA methylation changes in peripheral tissue following
63 therapy, and we suggest that previous findings are most likely explained by differences in cell
64 composition.

65

66 Introduction

67 The concept of an environmentally regulated epigenome has attracted considerable attention in
68 the mental health field [1, 2]. Many psychopathologies have developmental origins, and epigenetic
69 processes have been suggested as targets for the effects of psychosocial adversity particularly in
70 early life. The epigenome is an umbrella term for a range of mechanisms involved in gene regula-
71 tion, including DNA methylation, histone modifications and regulation through non-coding RNA
72 molecules [3]. Epigenetic processes are essential for normal cellular differentiation and develop-
73 ment. Perturbations in these processes have been linked to different pathologies [4], including
74 mental disorders [5]. Both animal models and human studies have pointed to persistent epigenetic
75 changes in response to various stimuli. These changes, it has been argued, might reflect or medi-
76 ate the long-term effects of early risk exposure such as prenatal malnutrition on metabolic out-
77 comes [6]. Another often quoted example of epigenetic mediation is the programming of the neu-
78 roendocrine stress response by the degree of maternal care in rodents [7].

79 DNA methylation, which involves methylation of cytosines predominantly in cytosine-guanine
80 (CpG) dinucleotides, has long been thought to represent an early-established and rather stable
81 epigenetic marker. A number of recent studies have shown, however, that DNA methylation pat-
82 terns are more dynamic than previously thought, and can change in response to internal signals or
83 environmental influences [8-12]. These observations have sparked interest in the potential for psy-
84 chological and nutritional interventions (e.g. in Anorexia Nervosa) to influence these biological pro-
85 cesses.

86 Several studies have been published that assessed DNA methylation before and after therapeutic
87 intervention [see 13 for review]. Most followed a candidate-gene approach and investigated genes
88 involved in stress regulation, such as the *Glucocorticoid Receptor (NR3C1)* or *FKBP Prolyl*
89 *Isomerase 5 (FKBP5)* [14-16], or genes commonly investigated in psychiatric genetics studies,
90 such as the *Serotonin Transporter (SLC6A4; [17])*, *Monoamine Oxidase A (MAOA; [18])*, and the
91 *Brain Derived Neurotrophic Factor (BDNF; [19])*. The studies conducted so far are very heteroge-
92 neous in terms of investigated disorders (post-traumatic stress disorder, PTSD; anorexia nervosa,
93 AN; anxiety disorders, borderline personality disorder), analyzed tissue (buccal cells, whole blood,

94 peripheral blood mononuclear cells (PBMCs), as well as type of intervention and methodology for
95 exploring DNA methylation. A common feature of all investigations is the observation that therapy
96 responders and non-responders showed differential DNA methylation patterns pre- to post-
97 intervention. For instance, in combat veterans with PTSD, DNA methylation levels of *FKBP5* in
98 PBMC decreased in responders but increased in non-responders comparing pre- to post-therapy
99 measurements [16]. The first epigenome-wide investigation of intervention-associated DNA meth-
100 ylation changes in PTSD further supported this notion. Successful psychotherapeutic treatment of
101 PTSD was associated with increases in DNA methylation of the *Zinc Finger Protein 57* gene
102 (*ZFP57*) in whole blood, whereas DNA methylation in this region decreased during the develop-
103 ment of PTSD, and also decreased in patients who did not respond to therapy [20]. A similar pic-
104 ture emerged from an epigenome-wide study of AN. Here, longer duration of illness was associat-
105 ed with lower DNA methylation levels in whole blood, whereas DNA methylation increased at the
106 same positions with a concomitant increase in body mass index (BMI) across therapy [21].

107 Taken together, DNA methylation changes have thus been suggested as a marker or epigenetic
108 correlate of therapy outcome. Caution is needed in the interpretation of these findings though. With
109 exception of the two epigenome-wide association studies, only a limited number of CpGs were
110 investigated, the observed changes were small, and the applied methods mostly had insufficient
111 sensitivity to reliably assess such small DNA methylation differences. Furthermore, it is unclear
112 whether differences in DNA methylation, as observed after the intervention, do not rather reflect
113 changes in the cellular composition of the investigated tissue. DNA methylation patterns are highly
114 cell type-specific, and each cell type within a tissue contributes to DNA methylation variation [22].
115 Given that the cell composition of the circulating leukocyte pool is dynamic and influenced by vari-
116 ous external factors, including infections, menstrual cycle [23] or stress exposure [24], DNA meth-
117 ylation changes in blood collected at different time points from the same individual might primarily
118 reflect differences in cell composition [25], unrelated to the effect of intervention.

119 To address these limitations, we set out to investigate intervention-associated changes in DNA
120 methylation in a homogenous cell population (CD14⁺ monocytes), in a female-only PTSD patients
121 cohort. Monocytes were chosen as previous studies have shown that among the heterogeneous

122 leukocyte population, monocytes were the most sensitive subtype for traumatic experiences and
123 variation of psychosocial conditions [26].

124 The two goals of this study were, first, to replicate findings from previous reported intervention-
125 associated candidate genes (*NR3C1*, *FKBP5*, *SLC6A4*, *Oxytocin Receptor (OXTR)* in a female-
126 only PTSD cohort, and, second to identify new differentially methylated regions (DMRs) by per-
127 forming an exploratory whole-genome bisulfite sequencing (WGBS). For the exploratory WGBS we
128 not only analyzed a sub-sample of the PTSD cohort but also examined a second independent fe-
129 male AN cohort. AN has a metabolic component and therefore we expected to find more DMRs.
130 DNA methylation of commonly assessed candidate genes and promising targets from WGBS were
131 analyzed using targeted deep bisulfite sequencing (DBS). Our approach thus addressed essential
132 confounders, namely sex, cell heterogeneity, genetic variation, coverage of the genome and cov-
133 erage of CpGs within candidate genes.

134

135 **Results**

136 **Study 1 - Targeted analysis of previously investigated candidate genes**

137 To address our first goal of replicating intervention-associated DNA methylation changes of previ-
138 ously assessed candidate genes, we investigated sixty female PTSD patients. Patients with PTSD
139 had a clinically relevant reduction in PTSD symptoms, with a mean reduction of 15.6 ± 14.6 (SD)
140 on the PTSD-Check List [PCL-5; 27]. Thirty-six patients were classified as responder according to
141 PCL-5 (drop by 10 points from pre- to post-treatment). The responders showed a mean difference
142 between post- and pre-treatment in PCL-5 of -24.1 ± 10.3 , while the non-responders ($n=21$, 35%)
143 showed a mean difference of -1.0 ± 7.8 (PCL-5 data was missing for three patients).

144 DBS was performed for four candidate genes for which psychotherapy effects on DNA methylation
145 change have been previously reported: *NR3C1*, *FKBP5*, *SLC6A4* and *OXTR* (see S1 Fig for exact
146 chromosomal locations). Linear regression analysis showed no significant association between
147 pre-treatment mean DNA methylation of DBS targets and the severity of baseline PTSD symptoms
148 (S3 Table). Likewise there were no statistically significant differences in mean DNA methylation

149 between pre- and post-intervention for all investigated targets, even without correction for multiple
150 comparisons (all $p > .05$; Table 1). Intervention-associated changes in DNA Methylation of single
151 CpGs did not survive correction for multiple testing (S4 Table). Bayes factors favored the null hy-
152 pothesis of no DNA methylation change for *NR3C1* and *FKBP5*. Furthermore, DNA methylation
153 change was not conditional on therapy response (all $p > 0.16$; Table 1), with all Bayes factors larg-
154 er than one and Bayes factors for *SLC6A4* and *FKBP5* above the threshold of three. Moreover, we
155 observed no statistically significant correlation between symptom changes and DNA methylation
156 changes (all $p > 0.15$; Table 2 and S2 Fig, upper row), with all Bayes factors larger than one and
157 Bayes factors for *SLC6A4* and *FKBP5* above three. Distributions of DNA methylation changes are
158 shown in Fig 1, upper row by responder status. The largest mean differences between time points
159 was found for *OXTR* ($-0.26\% \pm 1.21\%$), and the smallest was $-0.019\% \pm 0.19\%$ for *NR3C1*. Mean
160 DNA methylation levels pre- and post-intervention averaged across the analyzed genomic regions
161 are shown in S3 Fig.

162 Complementary to the Bayes factor approach, equivalence test help infer whether true population
163 effect sizes are smaller than a pre-defined smallest effect size of interest. Effect sized for all candi-
164 date genes were significantly smaller than 1% DNA methylation change, even in the therapy-
165 responder group and after Bonferroni correction (all $p_{corrected} < .001$). The 95% confidence intervals
166 of difference scores in the responder group did not include methylation changes larger than
167 $\approx |0.5\%|$: $\Delta_{FKBP5} = 0.06\% [-0.28, 0.40]$, $\Delta_{SLC6A4} = -0.11\% [-0.33, 0.11]$, $\Delta_{OXTR} = -0.16\% [-0.52, 0.21]$,
168 $\Delta_{NR3C1} = 0.00\% [-0.06, 0.07]$.

169 We conclude that true effect sizes of all classic candidate genes are smaller than 1% DNA methyl-
170 ation change.

171

172 **Study 2 - Explorative whole-genome bisulfite sequencing**

173 In addition to our goal of conceptually replicating previously reported results in candidate genes,
174 we aimed to explore whether we could identify genomic regions with large pre-post intervention
175 changes in DNA methylation in a limited sample, which could then be validated in the larger sam-
176 ple. Besides the PTSD patients, we included AN patients for explorative WGBS. Due to the strong

177 metabolic component during AN therapy, we expected a higher number of DMRs in the AN pa-
178 tients. Following recommendations by Ziller et al. [28], we sequenced at least two biological repli-
179 cates at >5x coverage. Pre- and post-intervention monocyte DNA from two patients with PTSD and
180 additionally from three AN patients was subjected to WGBS. The patients for the WGBS were se-
181 lected based on their responsiveness to the therapy, absence of co-morbidity, and non-smoking
182 status.

183 There was a slight difference in the genome-wide mean methylation levels between the PTSD and
184 AN samples (0.72 vs. 0.75; Mann-Whitney U test; S5 Table). DNA methylation did not differ be-
185 tween pre- and post-intervention samples of the same individuals (p-value = 1; Wilcoxon signed
186 rank test).

187 A principal component analysis (PCA) of the PTSD and AN methylomes did not group samples
188 according to pre- or post-intervention state (S4 Fig). The same was observed in a cluster analysis
189 of the 1,000 most variable CpGs for the PTSD and AN datasets, in which separate branches are
190 observed for each individual (Fig 2). We observed large differences between individuals, most like-
191 ly reflecting the different genetic backgrounds, but no recurrent differences between the pre- and
192 post-intervention states.

193 To identify DMRs between pre- and post-treatment samples from each cohort, we used two differ-
194 ent bioinformatic tools (camel and metilene; [29, 30]). Owing to lower coverage in the PTSD sam-
195 ples compared to the AN samples, we set the threshold to a minimum coverage of five reads and
196 ten reads, respectively. Defining a camel DMR as a region with at least four CpGs and a minimum
197 methylation difference of 0.3, we detected 33 DMRs in the PTSD patients (S6 Table). Using a filter
198 of $q < 0.05$ for metilene DMRs, we detected four DMRs (S7 Table).

199 Using the same DMR filters, camel identified no DMRs in the AN data set, indicating that there are
200 no major recurrent methylation changes. Since the samples of this cohort were sequenced at a
201 higher depth, we decided to lower the minimum methylation difference between groups to 0.2 while
202 at the same time increasing stringency by setting the minimum number of CpGs to 10. Using these
203 filters, we identified 35 DMRs with camel (S8 Table). At $q < 0.05$, metilene reported 10 DMRs, with
204 seven DMRs being detected by both tools (S9 Table). There is one DMR common to the PTSD

205 and AN datasets, which overlaps the binding sites for CTCF and other transcription factors within
206 intron 1 of *EXD3*, a gene encoding an exoribonuclease required for 3'-end trimming of AGO1-
207 bound miRNAs.

208 **Validation of WGBS-nominated targets in the PTSD sample.** DNA methylation pattern of four
209 targets that emerged as potentially responsive to intervention from WGBS data were validated in
210 the entire sample (n=60) using DBS. The following gene regions were analyzed: DMR-4 within
211 *Adenosine A1 Receptor (ADORA1)*, DMR-21 within *Tetraspanin 9 (TSPAN9)*, DMR-10 within *Ri-*
212 *bosomal Protein S6 Kinase A2 (RPS6KA2)*, and intergenic DMR-1 (S6 Table). Chromosomal loca-
213 tions of the targets are shown in S1 Fig.

214 The effect sizes of *ADORA1*, *RPS6KA2*, and DMR-1 were all significantly smaller than 5% DNA
215 methylation change in both the whole cohort and the responder cohort (all $p_{corrected} < .001$). The
216 effect of *TSPAN9* was only significantly different from 5% in the whole cohort on an uncorrected
217 $p = .043$, which did not survive Bonferroni correction. There were no statistically significant differ-
218 ences in DNA methylation between pre- and post-intervention for the WGBS-nominated targets.
219 However, the possibility of a true effect size within the range of 5% DNA methylation difference at
220 the *TSPAN9* between pre- and post-intervention samples cannot be ruled out. Bayes factors fa-
221 vored the null hypothesis of no methylation change for *RPS6KA2* and DMR-1. Similar to candidate
222 genes, DNA methylation change was not conditional on therapy response (all $p > 0.05$; Table 1),
223 with all Bayes factors larger than one and Bayes factors for DMR-1 above the threshold of three.
224 There were no statistically significant correlations between symptom changes and DNA methyla-
225 tion changes (all $p > 0.05$; Table 2 and S2 Fig, lower row), with all Bayes factors larger than one.
226 Distributions of DNA methylation changes are shown in Fig 1, lower row by responder status. The
227 largest mean differences between time points was found for *TSPAN9* ($-2.78\% \pm 9.78\%$), and the
228 smallest was $-0.12\% \pm 3.35\%$ for DMR-1. Mean DNA methylation levels pre- and post-intervention
229 averaged across the analyzed genomic regions are shown in S3 Fig. DNA methylation levels for
230 single CpGs are shown in S4 Table.

231 Equivalence tests showed that the effect sizes of *ADORA1*, *RPS6KA2*, and DMR-1 were all signifi-
232 cantly smaller than 5% DNA methylation change in both the whole cohort and the responder cohort

233 (all $p_{corrected} < .001$). The effect of *TSPAN9* was only significantly different from 5% in the whole co-
234 hort on an uncorrected $p = .043$, which did not survive Bonferroni correction. Hence, although we
235 cannot rule out that there is a true effect size as large as 5% DNA methylation change for the
236 *TSPAN9* locus, we can conclude with relative certainty that true effect sizes of the WGBS nomi-
237 nated genes are smaller than 5%.

238

239 **Validation of WGBS-nominated targets in the AN sample.** In the AN cohort, DBS was per-
240 formed for validation of targets that emerged from WGBS (methylation difference ≥ 0.2) in all three
241 individuals as potentially responsive to weight gain in eight regions (four detected by both DMR-
242 calling tools and four detected by camel: DMR-1 within *Galactosidase Beta 1 Like (GLB1L)*,
243 intergenic DMR-3, DMR-7 within *Family With Sequence Similarity 50 Member B (FAM50B)*, DMR-
244 11 within *Mesoderm Specific Transcript (MEST)*, DMR-13 within *ER Lipid Raft Associated 2*
245 (*ERLIN2*), DMR-16 within *Exonuclease 3'-5' Domain Containing 3 (EXD3)*, DMR-22 within *SNRPN*
246 *Upstream Reading Frame/ Small Nuclear Ribonucleoprotein Polypeptide N (SNURF/SNRPN)* and
247 DMR-28 within *Heat Shock Protein Family A (Hsp70) Member 12B (HSPA12B)* (for DMR number-
248 ing see S8 Table). All CpGs contained in the DMRs were included in the amplicons. Chromosomal
249 locations are shown in S2 Table.

250 Since for this cohort we had used a lower minimum methylation difference between groups (0.2),
251 we first attempted technical confirmation using DBS in the same three individuals (pre- and post-
252 treatment; same DNA preparation as for WGBS). As can be seen in S5 Fig, the methylation differ-
253 ences identified by WGBS could not be confirmed in any of these regions. Therefore, the four in-
254 dependent samples were not further analyzed.

255

256 Discussion

257 Epigenetic processes have been proposed as a potential mechanism mediating the link between
258 exposure to trauma or adversity and mental health problems. Expectedly, there is great interest in
259 the question whether psychological interventions translate into a modification of disorder-related
260 epigenetic signatures. The first few studies addressing this question have found divergent patterns

261 of DNA methylation changes between patients who responded to therapy and those who did not.
262 However, results of these pilot studies remain inconclusive, because differences in genetic back-
263 ground and changes in cell composition over time, which are the main confounders in epigenetic
264 research, were not taken into account.

265 In our study, we avoided these confounders by using isogenic pre- and post-treatment samples
266 and a homogenous cell population (monocytes). Furthermore, we used DBS for targeted high
267 resolution methylation analysis. With this approach, we could not identify any evidence of interven-
268 tion-associated changes in DNA methylation. We investigated four candidate genes that were pre-
269 viously shown to be sensitive to variation in the social environment and/or seemed responsive to
270 intervention in a sample of female PTSD patients. The prime candidate for epigenetic research in
271 humans has been *NR3C1*, since DNA methylation of the promoter of alternative Exon 1₇ (1F in
272 humans) had been shown to vary as a function of maternal care in the rodent model [7]. We found
273 no change between pre- and post-intervention in PTSD patients and no differences between ther-
274 apy responders and non-responders. We also investigated DNA methylation of *SLC6A4*, the most
275 widely studied candidate gene in psychiatry. One previous study found small increases in *SLC6A4*
276 methylation in therapy responders in one of four assessed CpG sites [17]. Here, we investigated
277 82 CpGs sites across the entire CpG island in the gene's promoter region and found no evidence
278 for change over time - neither overall nor when stratified by responders and non-responders. This
279 was also true for *FKBP5*, where we focused on 5 CpGs in intron 7, previously associated with
280 PTSD risk following early life adversity [31], and the *OXTR* gene, where we investigated 16 CpGs
281 in a putative enhancer region - characterized by H3K27 acetylation peaks - in intron 3 of the gene.
282 In sum, we did not observe intervention-associated changes in DNA methylation of commonly in-
283 vestigated candidate genes when assessed in a homogenous cell population.

284 In small samples with limited statistical power, non-significant results do not provide evidence for
285 the absence of meaningful effects. We thus further conducted equivalence tests to ascertain
286 whether observed effect sizes are significantly smaller than a minimal effect size of interest. These
287 revealed that DNA methylation changes of the four candidate genes were significantly below phys-
288 iologically meaningful levels [32, 33]. Notably, this does not preclude that miniscule changes on

289 these genes might contribute to a meaningful epigenome-wide poly-epigenetic score, but such
290 studies necessitate much larger samples and another theoretical perspective on the importance of
291 single candidate genes than the studies whose effects we aimed to replicate.

292 Candidate gene studies can only provide a very limited view on potential dynamics of the
293 epigenome. True epigenome-wide studies covering the ~28 million CpG sites across the human
294 genome are still prohibitive in large cohorts because of the associated costs. Here, we used an
295 explorative strategy to identify genomic regions whose DNA methylation pattern might potentially
296 be responsive to intervention, by using WGBS in two PTSD and three AN patients before and after
297 therapy. We identified a small number of pre-to-post intervention DMRs (36 for PTSD and 38 for
298 AN). The validation of a subset of the identified PTSD DMRs in the remaining 58 patients could not
299 confirm the potential differential methylation patterns found by WGBS. In addition, AN DMRs iden-
300 tified after reducing the stringency in DMR calling (by lowering to 0.2 the minimum methylation
301 difference allowed) could not be validated by DBS in the three samples subjected to WGBS.

302 It is remarkable that the change of physiological conditions for monocytes in AN due to adaption to
303 prolonged starvation is not associated with significant changes in DNA methylation pattern. This
304 suggests that cell type-specific methylation patterns are highly stable. This stability can probably
305 be attributed to stem or progenitor cells, because monocytes have a very short half-life in blood.
306 Pre- and post-treatment samples are not drawn from the same pool of monocytes, but are derived
307 from the same stem or progenitor cells. We previously showed differences in metabolic profiles in
308 patients with AN compared to controls and in patients with AN between acute stage of starvation
309 and after short term weight recovery. A substantial number of metabolite levels did not return to
310 normal after short term recovery [34]. It might be assumed that weight gain could exert an effect on
311 the methylome at a later time point.

312 It is important to reflect on the question whether it is plausible to expect changes of DNA methyl-
313 ation patterns in peripheral surrogate tissues that are associated with changes in thoughts, feelings
314 or somatic alterations in a meaningful way. Three scenarios have been put forward previously:
315 first, DNA methylation dynamics observed in blood or buccal epithelial cells reflect the processes
316 occurring in neuronal cells [18]. However, as buccal epithelium or leukocytes do not have a biolog-

317 ically realistic link to cellular processes occurring in neurons, these transient and activity-
318 dependent alterations of chromatin and the specific patterns of DNA methylation in neurons are
319 most likely not reflected in peripheral tissue.

320 The second scenario is that changes in peripheral DNA methylation patterns are brought about by
321 intervention-associated psychophysiological changes that parallel changes in thoughts and feel-
322 ings. Such cross talk between the central nervous system and peripheral organs is arguably medi-
323 ated through regulation of the autonomic nervous system and the hypothalamic–pituitary–adrenal
324 axis, activating the two main stress effectors noradrenaline and cortisol. These mediate their ef-
325 fects by engaging cellular receptor systems, which ultimately regulate specific gene expression
326 responses. A testable model therefore suggests that changes in DNA methylation are brought
327 about by alterations of transcriptional activity associated with changes in upstream signaling of
328 stress mediators such as cortisol or noradrenalin [35].

329 The third scenario, which is in our opinion the most plausible explanation for many previous find-
330 ings, is that changes in DNA methylation levels merely reflect changes in cell composition, which
331 might be stochastic in nature, reflect differences in health status independent of disorder of inter-
332 est, or reflect intervention-associated physiological changes. As such, change in the composition
333 of the leukocyte pool might be a marker of therapy response [36].

334 The following limitations deserve a mention. The costs associated with WGBS limited the number
335 of patients to 2-3 for each cohort, so that only large pre-to-post differences could be reliably identi-
336 fied. Power estimates show that we had 80% power to detect pre-to-post-treatment DNA methyl-
337 ation differences of 30%. Furthermore, only one cell type was investigated. Monocytes have been
338 shown as the most sensitive subtype for social conditions and traumatic experiences, at least in
339 terms of transcriptional changes [26, 37-39]. However, any effects in other cell types (e.g., T cells,
340 B cells, NK cells, etc.), or changes in the relative prevalence of cells in the circulating leukocyte
341 pool are missed in this analysis.

342 In conclusion, our results provide no evidence in support of intervention-associated changes in
343 DNA methylation in monocytes in PTSD or AN, and equivalence tests and Bayesian statistics pro-
344 vided evidence against even subtle DNA methylation changes associated with therapy outcome.

345 We argue that the previously reported changes in DNA methylation following therapy are most
346 likely explained by changes in cell composition rather than by cellular reprogramming of DNA
347 methylation. In itself, any shifts in cellular composition might reflect intervention-associated physio-
348 logical changes and could therefore be used as biomarkers, but markers should not be confused
349 with mechanisms.

350

351 **Methods**

352 **Sample Characteristics, clinical judgement and treatment**

353 **PTSD cohort.** We investigated sixty female in-patients of European descent seeking treatment for
354 PTSD at the Department of Psychosomatic Medicine and Psychotherapy, LWL-University Hospital,
355 Ruhr-University Bochum. The patients were between 20 and 60 years old (mean age: 40.0 ± 11.9
356 (SD) years), and the mean treatment duration was 6.5 ± 1.4 (SD) weeks. Inclusion criteria were
357 PTSD diagnosis and female sex. The PTSD study was approved by the ethics committee of the
358 Faculty of Psychology, Ruhr University Bochum (Nr. 155), and patients gave written informed con-
359 sent (see S1 Table for more details).

360 All patients with PTSD were diagnosed with ICD-10 (F43.1; International Classification of Disease-
361 es, 10th revision, WHO, 1993) prior to in-patient admission via structured clinical interviews in the
362 outpatient department of the hospital. Furthermore, symptoms of PTSD were recorded before and
363 after in-patient treatment with the PCL-5.

364 Participants of the PTSD cohort received standard in-patient PTSD treatment. This involved one
365 session each week of individual cognitive-behavioral therapy, three sessions of trauma group ther-
366 apy, two sessions of trauma stabilization group therapy, one session of a “skills group”, two ses-
367 sions of kinesitherapy, two sessions of art therapy, physiotherapy, clinical rounds, and daily short
368 sessions with a nurse. During individual therapy sessions patients received different trauma expo-
369 sure methods. Overview of the study design is shown in Fig 3.

370 **AN cohort.** The second cohort comprised seven female adolescent patients with AN, receiving in-
371 patients treatment at the University Hospital Essen, University of Duisburg-Essen. The median age

372 was 16 (with first and third quartile: Q1, Q3; 15, 17) years, median height 162.5 (160.2, 167.7) cm,
373 median weight at admission 40.2 (37.6, 46.7) kg, median BMI at admission 15.2 (14.8, 16.1) kg/m².
374 Length of treatment was 94 (69, 99) days (see S1 Table 1 for sample characteristics). Inclusion
375 criteria for the AN group were a diagnosis of AN, female sex, German ancestry and age from 12 to
376 18 years. The AN study was approved by the ethics committee of the Faculty of Medicine, Univer-
377 sity Hospital Essen (Nr. 06-3212 amendment of November 2016). Patients and their parents gave
378 written informed consent. Patients with AN were examined at the Department of Child and Adoles-
379 cent Psychiatry, Psychosomatics and Psychotherapy, University Hospital Essen, University of
380 Duisburg-Essen according to Diagnostic and Statistical Manual of Mental Disorders, fourth edition,
381 text revision (DSM-IV-TR) criteria [40]. AN diagnosis was confirmed via clinical examination and a
382 semi structured interview (Kiddie Schedule for Affective Disorders and Schizophrenia (K-SADS
383 [41]). Adolescent patients with AN participated in a multimodal multidisciplinary treatment program
384 based on dialectical behavioral therapy for adolescents that included weight restoration, individual
385 nutritional counseling, individual therapy (twice a week), skills-groups and individual skill training
386 (twice a week), family sessions (fortnightly), and a group psychoeducation program for parents
387 (monthly). During weight restoration, patients received nutritional counselling and meal support
388 training. Therapy goals were a weight gain of at least 500g per week and a minimum target weight
389 in the range of the 10-20th age-adjusted BMI percentile.

390 Patients with AN had a median BMI at admission of 15.2 (14.8, 16.1) kg/m² and median BMI at end
391 of treatment was 17.5 (17.5, 17.8) kg/m². During the treatment period (i.e. hospital stay) of a medi-
392 an of 94 (69, 99) days, all seven patients gained considerable weight (median weight gain 5.8 (5.6,
393 6.7) kg; median BMI gain 2.2 (2.0, 2.4) kg/m²).

394

395 **Sample preparation and targeted deep bisulfite sequencing**

396 Nine ml blood was drawn in the morning between 7-9 am (S-Monovette 9 ml K3E, Sarstedt). Mon-
397 ocytes were immunomagnetically purified from whole blood with the MACS System (Miltenyi
398 Biotec, Bergisch Gladbach, Germany), shock frozen and stored at -80°C. DNA was isolated with
399 the AllPrep RNA/DNA Mini Kit (Qiagen, Hilden, Germany). For DBS, DNA was bisulfite-modified

400 with the EZ DNA Methylation Gold Kit (Zymo Research, Orange, CA, USA) and processed as de-
401 scribed elsewhere [42, 43] using primers as indicated in S2 Table.

402

403 **Whole-genome bisulfite sequencing**

404 For PTSD samples, WGBS libraries were prepared as previously described [44]. For the AN sam-
405 ples, 5 μ g DNA at 50 ng/ μ l in water was used for library preparation and NGS sequencing on a
406 HiSeq X platform (DKFZ Genomics & Proteomics Core Facility (GPCF) with 1 sample per lane.
407 Read data from both datasets were processed as described previously [45, 46]. As a reference
408 genome, we used hg19. For calling DMRs, we used camel [30] and metilene [29].

409

410 **Statistical Analyses**

411 Repeated measures analyses of variance (ANOVA) were performed to assess changes in DNA
412 methylation. Therapy response was included as an additional between-subject factor to check for
413 therapy outcome-dependent changes in DNA methylation. Moreover, Pearson correlations were
414 computed between percent DNA methylation change and PCL-5 symptom change to test a contin-
415 uous measure of therapy response. In addition to changes over time, linear regression analysis
416 was performed with pre-treatment mean DNA methylation of DBS targets and severity of baseline
417 PTSD symptoms.

418 Our sample size of $N = 60$ was based on the average sample size of previous studies in therapy-
419 contingent DNA methylation changes in mental disorders ($M = 69$, range = 16-115). Due to the
420 heterogeneity of reported effect sizes, statistical tests, designs, and populations, a principled effect
421 size estimation based on previous studies was not suitable in our case. We thus performed a sen-
422 sitivity analysis with the software *gpower* [47], which showed acceptable statistical power ($\beta = .80$)
423 to detect small changes from pre- to post-treatment at $\eta^2 = .03$, assuming a correlation between
424 pre- and post-intervention methylation of $r = .50$. For comparisons between responders and non-
425 responders or correlations between symptom change and methylation change, moderate effect
426 sizes at $\eta^2 = .09$ can be detected with sufficient statistical power, which is still in the range of previ-
427 ously reported effect sizes [13].

428 Generally, non-significant results do not provide evidence for the null hypothesis (i.e. absence of
429 effect), especially when the statistical power is limited. Therefore, p-values were supplemented
430 with Bayes factors to quantify the evidence for the null hypothesis using the BayesFactor package
431 (v0.9.12-4.2) in R (3.6.1) and non-informative default priors [48, 49].

432 Complementary to the Bayesian approach, we conducted equivalence tests to assess whether
433 effect sizes in DNA methylation change are significantly smaller than the smallest biologically
434 meaningful effect size. It has been argued that DNA methylation below 5% should be interpreted
435 with extreme caution [32, 33]. We used the two one-tailed t-test procedure [50] to check whether
436 empirical effect sizes for methylation change are smaller than 5% or even a more conservative 1%.
437 For a detailed account of statistical methods please see S2 Methods.

438

439 **Acknowledgement**

440 We thank the Cologne Center for Genomics (CCG) and the DKFZ Genomics & Proteomics Core
441 Facility (GPCF) for performing WGBS.

442

443

444 **References**

- 445 1. Szyf M. The early life social environment and DNA methylation: DNA methylation mediating the
446 long-term impact of social environments early in life. *Epigenetics* 2011; **6**(8): 971-978.
447
- 448 2. Hubel C, Marzi SJ, Breen G, Bulik CM. Epigenetics in eating disorders: a systematic review. *Mol*
449 *Psychiatry* 2019; **24**(6): 901-915.
450
- 451 3. Allis CD, Jenuwein T. The molecular hallmarks of epigenetic control. *Nat Rev Genet* 2016; **17**(8):
452 487-500.
453
- 454 4. Godfrey KM, Costello PM, Lillycrop KA. The developmental environment, epigenetic biomarkers
455 and long-term health. *J Dev Orig Health Dis* 2015; **6**(5): 399-406.
456
- 457 5. McGowan PO, Szyf M. The epigenetics of social adversity in early life: implications for mental
458 health outcomes. *Neurobiol Dis* 2010; **39**(1): 66-72.
459
- 460 6. Tobi EW, Slieker RC, Luijk R, Dekkers KF, Stein AD, Xu KM *et al*. DNA methylation as a media-
461 tor of the association between prenatal adversity and risk factors for metabolic disease in adulthood. *Sci Adv*
462 2018; **4**(1): eaao4364.
463
- 464 7. Weaver IC, Cervoni N, Champagne FA, D'Alessio AC, Sharma S, Seckl JR *et al*. Epigenetic pro-
465 gramming by maternal behavior. *Nat Neurosci* 2004; **7**(8): 847-854.
466
- 467 8. Dekkers KF, van Ijzerman M, Slieker RC, Moed MH, Bonder MJ, van Galen M *et al*. Blood lipids
468 influence DNA methylation in circulating cells. *Genome Biol* 2016; **17**(1): 138.
469
- 470 9. Emeny RT, Baumert J, Zannas AS, Kunze S, Wahl S, Iurato S *et al*. Anxiety Associated Increased
471 CpG Methylation in the Promoter of *Asb1*: A Translational Approach Evidenced by Epidemiological and
472 Clinical Studies and a Murine Model. *Neuropsychopharmacology* 2018; **43**(2): 342-353.

473

474 10. Joehanes R, Just AC, Marioni RE, Pilling LC, Reynolds LM, Mandaviya PR *et al.* Epigenetic Signa-
475 tures of Cigarette Smoking. *Circ Cardiovasc Genet* 2016; **9**(5): 436-447.

476

477 11. Saunderson EA, Spiers H, Mifsud KR, Gutierrez-Mecinas M, Trollope AF, Shaikh A *et al.* Stress-
478 induced gene expression and behavior are controlled by DNA methylation and methyl donor availability in
479 the dentate gyrus. *Proc Natl Acad Sci U S A* 2016; **113**(17): 4830-4835.

480

481 12. Wong CC, Caspi A, Williams B, Craig IW, Houts R, Ambler A *et al.* A longitudinal study of epige-
482 netic variation in twins. *Epigenetics* 2010; **5**(6): 516-526.

483

484 13. Kumsta R. The role of epigenetics for understanding mental health difficulties and its implications
485 for psychotherapy research. *Psychol Psychother* 2019; **92**(2): 190-207.

486

487 14. Roberts S, Keers R, Lester KJ, Coleman JR, Breen G, Arendt K *et al.* Hpa Axis Related Genes and
488 Response to Psychological Therapies: Genetics and Epigenetics. *Depress Anxiety* 2015; **32**(12): 861-870.

489

490 15. Roberts S, Keers R, Breen G, Coleman JRI, Johren P, Kepa A *et al.* DNA methylation of FKBP5
491 and response to exposure-based psychological therapy. *Am J Med Genet B Neuropsychiatr Genet* 2019;
492 **180**(2): 150-158.

493

494 16. Yehuda R, Daskalakis NP, Desarnaud F, Makotkine I, Lehrner AL, Koch E *et al.* Epigenetic Bi-
495 omarkers as Predictors and Correlates of Symptom Improvement Following Psychotherapy in Combat Vet-
496 erans with PTSD. *Front Psychiatry* 2013; **4**: 118.

497

498 17. Roberts S, Lester KJ, Hudson JL, Rapee RM, Creswell C, Cooper PJ *et al.* Serotonin transporter
499 [corrected] methylation and response to cognitive behaviour therapy in children with anxiety disorders.
500 *Transl Psychiatry* 2014; **4**: e444.

501

- 502 18. Ziegler C, Richter J, Mahr M, Gajewska A, Schiele MA, Gehrmann A *et al.* MAOA gene
503 hypomethylation in panic disorder-reversibility of an epigenetic risk pattern by psychotherapy. *Transl Psy-*
504 *chiatry* 2016; **6**: e773.
- 505
- 506 19. Perroud N, Salzmann A, Prada P, Nicastrò R, Hoeppli ME, Furrer S *et al.* Response to psychothera-
507 py in borderline personality disorder and methylation status of the BDNF gene. *Transl Psychiatry* 2013; **3**:
508 e207.
- 509
- 510 20. Vinkers CH, Geuze E, van Rooij SJH, Kennis M, Schur RR, Nispeling DM *et al.* Successful treat-
511 ment of post-traumatic stress disorder reverses DNA methylation marks. *Mol Psychiatry* 2019.
- 512
- 513 21. Steiger H, Booij L, Kahan, McGregor K, Thaler L, Fletcher E *et al.* A longitudinal, epigenome-wide
514 study of DNA methylation in anorexia nervosa: results in actively ill, partially weight-restored, long-term
515 remitted and non-eating-disordered women. *J Psychiatry Neurosci* 2019; **44**(3): 205-213.
- 516
- 517 22. Farre P, Jones MJ, Meaney MJ, Emberly E, Turecki G, Kobor MS. Concordant and discordant DNA
518 methylation signatures of aging in human blood and brain. *Epigenetics Chromatin* 2015; **8**: 19.
- 519
- 520 23. Nowak J, Borkowska B, Pawlowski B. Leukocyte changes across menstruation, ovulation, and mid-
521 luteal phase and association with sex hormone variation. *Am J Hum Biol* 2016; **28**(5): 721-728.
- 522
- 523 24. Cole SW. Elevating the perspective on human stress genomics. *Psychoneuroendocrinology* 2010;
524 **35**(7): 955-962.
- 525
- 526 25. Jones MJ, Moore SR, Kobor MS. Principles and Challenges of Applying Epigenetic Epidemiology
527 to Psychology. *Annu Rev Psychol* 2018; **69**: 459-485.
- 528

- 529 26. Cole SW, Hawkley LC, Arevalo JM, Cacioppo JT. Transcript origin analysis identifies antigen-
530 presenting cells as primary targets of socially regulated gene expression in leukocytes. *Proc Natl Acad Sci U*
531 *S A* 2011; **108**(7): 3080-3085.
- 532
- 533 27. Weathers FW, Litz BT, Keane TM, Palmieri PA, Marx BP, Schnurr PP. The PTSD Checklist for
534 DSM-5 (PCL-5). *Scale available from the National Center for PTSD at www.ptsd.va.gov* 2013.
- 535
- 536 28. Ziller MJ, Hansen KD, Meissner A, Aryee MJ. Coverage recommendations for methylation analysis
537 by whole-genome bisulfite sequencing. *Nat Methods* 2015; **12**(3): 230-232, 231 p following 232.
- 538
- 539 29. Juhling F, Kretzmer H, Bernhart SH, Otto C, Stadler PF, Hoffmann S. metilene: fast and sensitive
540 calling of differentially methylated regions from bisulfite sequencing data. *Genome Res* 2016; **26**(2): 256-
541 262.
- 542
- 543 30. Schröder C. Bioinformatics from genetic variants to methylation. 2018.
- 544
- 545 31. Klengel T, Mehta D, Anacker C, Rex-Haffner M, Pruessner JC, Pariante CM *et al.* Allele-specific
546 FKBP5 DNA demethylation mediates gene-childhood trauma interactions. *Nat Neurosci* 2013; **16**(1): 33-41.
- 547
- 548 32. Michels KB, Binder AM, Dedeurwaerder S, Epstein CB, Grealley JM, Gut I *et al.* Recommendations
549 for the design and analysis of epigenome-wide association studies. *Nat Methods* 2013; **10**(10): 949-955.
- 550
- 551 33. Leenen FA, Muller CP, Turner JD. DNA methylation: conducting the orchestra from exposure to
552 phenotype? *Clin Epigenetics* 2016; **8**: 92.
- 553
- 554 34. Föcker M, Timmesfeld N, Scherag S, Knoll N, Singmann P, Wang-Sattler R *et al.* Comparison of
555 metabolic profiles of acutely ill and short-term weight recovered patients with anorexia nervosa reveals al-
556 terations of 33 out of 163 metabolites. *J Psychiatr Res* 2012; **46**(12): 1600-1609.
- 557

- 558 35. Zannas AS, Chrousos GP. Epigenetic programming by stress and glucocorticoids along the human
559 lifespan. *Mol Psychiatry* 2017; **22**(5): 640-646.
560
- 561 36. Holbrook JD, Huang RC, Barton SJ, Saffery R, Lillycrop KA. Is cellular heterogeneity merely a
562 confounder to be removed from epigenome-wide association studies? *Epigenomics* 2017; **9**(8): 1143-1150.
563
- 564 37. Cole SW, Conti G, Arevalo JM, Ruggiero AM, Heckman JJ, Suomi SJ. Transcriptional modulation
565 of the developing immune system by early life social adversity. *Proc Natl Acad Sci U S A* 2012; **109**(50):
566 20578-20583.
567
- 568 38. O'Donovan A, Sun B, Cole S, Rempel H, Lenoci M, Pulliam L *et al.* Transcriptional control of mon-
569 ocyte gene expression in post-traumatic stress disorder. *Disease markers* 2011; **30**(2-3): 123-132.
570
- 571 39. Powell ND, Sloan EK, Bailey MT, Arevalo JM, Miller GE, Chen E *et al.* Social stress up-regulates
572 inflammatory gene expression in the leukocyte transcriptome via beta-adrenergic induction of myelopoiesis.
573 *Proc Natl Acad Sci U S A* 2013; **110**(41): 16574-16579.
574
- 575 40. (2000). APA. Diagnostic and statistical manual of mental disorders (4th ed., Text Revision): Wash-
576 ington, 2000.
577
- 578 41. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P *et al.* Schedule for Affective Disorders
579 and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): initial reliability
580 and validity data. *J Am Acad Child Adolesc Psychiatry* 1997; **36**(7): 980-988.
581
- 582 42. Rahmann S, Beygo J, Kanber D, Martin M, Horsthemke B, Buiting K. Amplikyzer: Automated
583 methylation analysis of amplicons from bisulfite flowgram sequencing. *PeerJ Preprints* 2013.
584

- 585 43. Moser DA, Müller S, Hummel EM, Limberg AS, Dieckmann L, Frach L *et al.* Targeted bisulfite
586 sequencing: A novel tool for the assessment of DNA methylation with high sensitivity and increased cover-
587 age. *Psychoneuroendocrinology* 2020.
- 588
- 589 44. Leitão E, Di Persio S, Laurentino S, Wöste M, Dugas M, Kliesch S *et al.* The sperm epigenome does
590 not display recurrent epimutations in patients with severely impaired spermatogenesis. *Clinical Epigenetics*
591 2020; **12**(1).
- 592
- 593 45. Rademacher K, Schroder C, Kanber D, Klein-Hitpass L, Wallner S, Zeschnigk M *et al.* Evolutionary
594 origin and methylation status of human intronic CpG islands that are not present in mouse. *Genome Biol*
595 *Evol* 2014; **6**(7): 1579-1588.
- 596
- 597 46. Wallner S, Schroder C, Leitao E, Berulava T, Haak C, Beisser D *et al.* Epigenetic dynamics of mon-
598 ocyte-to-macrophage differentiation. *Epigenetics Chromatin* 2016; **9**: 33.
- 599
- 600 47. Faul F, Erdfelder E, Lang AG, Buchner A. G*Power 3: a flexible statistical power analysis program
601 for the social, behavioral, and biomedical sciences. *Behav Res Methods* 2007; **39**(2): 175-191.
- 602
- 603 48. Rouder JN, Morey RD, Speckman PL, Province JM. Default Bayes factors for ANOVA designs.
604 *Journal of Mathematical Psychology* 2012; **56**(5): 356–374.
- 605
- 606 49. Jarosz AF, Wiley J. What Are the Odds? A Practical Guide to Computing and Reporting Bayes Fac-
607 tors. *The Journal of Problem Solving* 2014; **7**(1): 1037–1040.
- 608
- 609 50. Lakens D. Equivalence Tests: A Practical Primer for t Tests, Correlations, and Meta-Analyses. *Soc*
610 *Psychol Personal Sci* 2017; **8**(4): 355-362.

611 **Supporting Information**

612

613 **S1 Methods. Cell homogeneity.**

614 **S2 Methods. Statistical analysis.**

615 **S1 Table. Sample Characteristics.**

616 **S2 Table. Primer Sequences.**

617 **S3 Table. Linear regression with pre-treatment mean DNA methylation and severity**
618 **of baseline PTSD symptoms.**

619 **S4 Table. Mean DNA methylation levels at single CpG sites.**

620 **S5 Table. WGBS descriptive information.**

621 **S6 Table. DMRs in the PTSD cohort identified with camel.**

622 **S7 Table. DMRs in the PTSD cohort identified with metilene.**

623 **S8 Table. DMRs in the AN cohort identified with camel.**

624 **S9 Table. DMRs in the AN cohort identified with metilene.**

625 **S1 Fig. Chromosomal location of analyzed regions of the PTSD cohort.**

626 **S2 Fig. Correlations between symptom change and DNA methylation change in the**
627 **PTSD cohort.**

628 **S3 Fig. Mean DNA Methylation of the PTSD cohort.**

629 **S4 Fig. Principal component analysis.**

630 **S5 Fig. DNA methylation differences of the AN cohort.**

631

632

633 **Tables**

634

Table 1. Effect of *intervention* and the effect of *intervention* by *responder* status interaction on DNA methylation in the PTSD cohort

	Intervention				Intervention x responder			
	<i>F</i>	<i>p</i>	η^2_G	BF_{01}	<i>F</i>	<i>p</i>	η^2_G	BF_{01}
A) Candidate Genes								
<i>NR3C1</i>	1.72	.196	.01	3.05	1.94	.170	.01	1.58
<i>SLC6A4</i>	1.25	.268	.00	2.69	0.01	.926	.00	3.65
<i>OXTR</i>	2.77	.102	.01	1.85	0.58	.449	.00	2.78
<i>FKBP5</i>	0.47	.494	.00	4.12	0.08	.784	.00	3.69
B) New Targets from WGBS								
<i>ADORA1</i>	3.52	.065	.01	0.64	0.61	.439	.00	2.75
<i>TSPAN9</i>	3.22	.078	.01	0.74	0.84	.363	.00	2.43
<i>RPS6KA2</i>	0.15	.701	.00	5.19	1.06	.308	.00	2.63
DMR-1	0.07	.790	.00	5.06	0.22	.640	.00	3.34

Note. Results from a mixed model analysis of variance. η^2_G = generalized eta squared. BF_{01} = Bayes factor quantifying the evidence for the null hypothesis against the alternative hypothesis. Bayes factors above 3 are interpreted as substantial evidence for the null hypothesis and shown in boldface. Numerator *df* = 1 for all tests. Denominator *df* for *NR3C1* = 51 and for *RPS6KA2* = 54 due to missing values. For all other genes denominator *df* = 55.

635

636

Table 2. Correlations between change in DNA methylation and change in symptom scores (PTSD cohort).

Gene	<i>r</i>	95% CI	<i>p</i>	<i>BF</i> ₀₁
A) Candidate Genes				
<i>NR3C1</i>	-.17	[-.42, .11]	.235	1.70
<i>SLC6A4</i>	-.02	[-.28, .24]	.874	3.30
<i>OXTR</i>	.11	[-.16, .36]	.425	2.50
<i>FKBP5</i>	-.04	[-.30, .22]	.778	3.22
B) New Targets from WGBS				
<i>ADORA1</i>	-.19	[-.43, .07]	.155	1.32
<i>TSPAN9</i>	.16	[-.11, .40]	.242	1.78
<i>RPS6KA2</i>	-.12	[-.37, .14]	.365	2.28
DMR-1	-.10	[-.35, .17]	.473	2.64

Note. *r* = pearson correlation. *BF*₀₁ = Bayes factor of For *NR3C1*, *n* = 53. For *RPS6KA2*, *n* = 56. For all remaining genes, *n* = 57. *BF*₀₁ = Bayes factor quantifying the evidence for the null hypothesis against the alternative hypothesis. Bayes factors above 3 are interpreted as substantial evidence for the null hypothesis and shown in boldface.

637

638 **Figure legends**

639

640 **Fig 1. Density plots for the distribution of DNA methylation change (post minus pre-**
641 **treatment) by therapy response and gene.**


642



643 **Fig 2. Cluster analysis of 1,000 most variable CpGs.** A) The PTSD monocyte methylomes were
644 obtained from two individuals (47 and 43), pre- (.1) and post-intervention (.2). B) The AN mono-
645 cyte methylomes were obtained pre- and post-treatment from three individuals (AN1, AN2 and
646 AN3). CpG SNPs were excluded from the analysis. The difference between individuals is much
647 greater than between pre- and post-intervention.

648


649 **Fig 3. Overview of the study design.**

Responder Non-responder



A**B**

A



B

